Viyash Scientific Limited (BOM:512529)
201.30
+7.20 (3.71%)
At close: Jan 22, 2026
Viyash Scientific Revenue
Viyash Scientific had revenue of 4.24B INR in the quarter ending September 30, 2025, with 15.01% growth. This brings the company's revenue in the last twelve months to 16.58B, up 14.39% year-over-year. In the fiscal year ending March 31, 2025, Viyash Scientific had annual revenue of 15.51B with 13.26% growth.
Revenue (ttm)
16.58B
Revenue Growth
+14.39%
P/S Ratio
5.29
Revenue / Employee
13.33M
Employees
1,244
Market Cap
87.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 15.51B | 1.82B | 13.26% |
| Mar 31, 2024 | 13.70B | -511.78M | -3.60% |
| Mar 31, 2023 | 14.21B | 80.93M | 0.57% |
| Mar 31, 2022 | 14.13B | 512.01M | 3.76% |
| Mar 31, 2021 | 13.62B | 1.82B | 15.47% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 76.18B |
| Granules India | 48.42B |
| Unichem Laboratories | 22.26B |
| FDC Limited | 20.77B |
| Caplin Point Laboratories | 20.42B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Rubicon Research | 14.36B |
Viyash Scientific News
- 2 months ago - Sequent Scientific Ltd (BOM:512529) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 2 months ago - Q2 2026 SeQuent Scientific Ltd Earnings Call Transcript - GuruFocus
- 2 months ago - SeQuent Scientific shares jump over 10% as NCLT approves merger with Viyash Lifesciences - Business Upturn
- 8 months ago - Sequent Scientific Q4 Results: Revenue up 11% YoY to Rs 401 crore - Business Upturn
- 1 year ago - Sequent Scientific Ltd (BOM:512529) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - GuruFocus
- 1 year ago - Sequent Scientific Q3 FY25 results: Revenue up 18.7% YoY to Rs 390.8 crore, Net profit declines 58.5% YoY - Business Upturn
- 1 year ago - India's Animal Healthcare Industry on a High-Growth Trajectory, Projected to Reach USD 2.0 Billion by 2034| Exclusive Report by Transparency Market Research Inc. - Benzinga
- 1 year ago - SeQuent Scientific consolidates ownership of subsidiaries in Sweden and Italy - Business Upturn